Skip to content

Advertisement

Volume 18 Supplement 1

19th Annual SCMR Scientific Sessions

  • Workshop presentation
  • Open Access

Myocardial tissue characteriation with native myocardial T1 mapping in SLE patients with chest pain

  • 1, 2,
  • 3,
  • 3,
  • 1,
  • 1, 2,
  • 3,
  • 4,
  • 3,
  • 4,
  • 3 and
  • 1, 4
Journal of Cardiovascular Magnetic Resonance201618 (Suppl 1) :W25

https://doi.org/10.1186/1532-429X-18-S1-W25

  • Published:

Keywords

  • Systemic Lupus Erythematosus
  • Systemic Lupus Erythematosus Patient
  • Obstructive Coronary Artery Disease
  • Systemic Lupus Erythematosus Disease Activity Index
  • Systemic Lupus Erythematosus Disease Activity

Background

Systemic Lupus Erythematosus (SLE) patients often exhibit signs and symptoms of cardiac ischemia with an overall increased prevalence of coronary artery disease (CAD), coronary microvascular dysfunction and myocarditis in this population. Potentially, these processes may be associated with subclinical changes in myocardial tissue. Elevated native myocardial T1 and extracellular volume (ECV), measures of myocardial fibrosis, have previously been shown in asymptomatic SLE patients, implying subclinical myocardial disease. We assessed the hypothesis that native myocardial T1 and ECV would be abnormally elevated in SLE subjects with chest pain.

Methods

We evaluated 13 women with SLE and with current or prior history of chest pain and no obstructive coronary disease and 11 matched normal controls using T1 mapping at 1.5T (Siemens Avanto). Native T1 maps were acquired in a single mid-ventricular slice with a 5(3)3 MOLLI sequence; post-contrast T1 maps were acquired in the same slice 10-15 minutes after contrast injection with a 4(1)3(1)2 MOLLI sequence. Healthy controls had a normal exercise stress test and no history of cardiovascular disease.

Results

The healthy control group (n = 11) and SLE group (n = 13) were well matched in age (50.5 ± 10.4 vs 46.4 ± 11, p = 0.374) and BMI (25.9 ± 4.5 vs 26.0 ± 7.6, p = 0.357). Eight SLE subjects had current or past corticosteroid use and 7 had current or past use of a cytotoxic agent. Seven SLE subjects had current chest pain while 6 were without. Average SLE duration was 19.5 years. Native myocardial T1 values were increased in the women with SLE with current or past chest pain compared to reference control women (1049.4 ± 34.4 vs 1003.2 ± 19.3 ms, p = 0.005) (Figure). ECV values were elevated compared to published values for normal controls using the same T1 mapping sequences at 1.5T (27.2 ± 3.6 vs 25.4 ± 2.5%). Native T1 values were increased in SLE subjects with current chest pain symptoms compared to those without, however not significantly (1056.3 ± 31.1 vs 1041.5 ± 31.1, p = 0.46). No significant difference in ECV was observed between SLE subjects with and without current chest pain symptoms. No significant relationship was shown between native myocardial T1 or ECV and age, BMI, disease duration, or SLEDAI (SLE Disease Activity Index). However, native myocardial T1 trended toward positive correlation with corticosteroid use (r = 0.507, p = 0.077) as well as the use of cytotoxic agents (r = 0.495, p = 0.086).

Conclusions

Among women with SLE, chest pain, and no obstructive coronary disease, native myocardial T1 measured by CMR is elevated consistent with diffuse fibrosis compared to controls. Further work will validate the presence of diffuse fibrosis with native T1 and ECV in women with SLE, chest pain, and no obstructive CAD.
Figure 1
Figure 1

Native myocardial T1 in SLE subjects with chest pain versus healthy controls (1003.2 ± 19.3 vs 1049.4 ± 34.4 ms, p = 0.005).

Authors’ Affiliations

(1)
Biomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
(2)
Bioengineering, University of California, Los Angeles, Los Angeles, CA, USA
(3)
Department of Medicine, Cedars-Sinai Medical Center, Los Angels, CA, USA
(4)
Barbra Streisand Women's Heart Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Copyright

© Shaw et al. 2016

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement